Sokal J E
Am J Hematol. 1976;1(4):493-500. doi: 10.1002/ajh.2830010414.
Median survival figures are essentially worthless for evaluation of the effectiveness of therapy in different series of patients with chronic myelocytic leukemia. Such data are heavily influenced by the characteristics of the initial patient mix, which play the major role in determining mortality during the first year of treatment. The effects of differing initial proportions of poor-risk patients are dissipated within two years, however, and the annual mortality rates thereafter reflect the influence of antileukemic therapy. Comparison of these rates, from very diverse series of patients, yielded quite consistent results and indicated superiority of effective chemotherapy over irradiation or inferior drug schedules.
对于评估不同系列慢性粒细胞白血病患者的治疗效果而言，中位生存期数据基本上毫无价值。这些数据受到初始患者构成特征的严重影响，而初始患者构成特征在决定治疗第一年的死亡率方面起主要作用。然而，高危患者不同初始比例的影响在两年内就会消散，此后的年死亡率反映了抗白血病治疗的影响。对来自非常不同系列患者的这些死亡率进行比较，得出了相当一致的结果，并表明有效化疗优于放疗或较差的药物治疗方案。
